Patents by Inventor G. Roger Thomas

G. Roger Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke
    Patent number: 7655230
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: February 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, legal representative, G. Roger Thomas
  • Co-Administration of a Thrombolytic and an Anti-CD18 Antibody in Stroke
    Publication number: 20090274689
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Application
    Filed: April 21, 2008
    Publication date: November 5, 2009
    Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, G. Roger Thomas
  • Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
    Patent number: 7361344
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: April 22, 2008
    Assignee: Genentech, Inc.
    Inventors: Martin M. Bednar, Linda Gross, legal representative, G. Roger Thomas, Cordell E. Gross
  • Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
    Publication number: 20040057951
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Application
    Filed: March 31, 2003
    Publication date: March 25, 2004
    Applicant: Genentech, Inc.
    Inventors: Martin M. Bednar, Cordell E. Gross, G. Roger Thomas, Linda Gross
  • Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
    Publication number: 20020081294
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an ant-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Application
    Filed: December 20, 2000
    Publication date: June 27, 2002
    Applicant: Genentech, Inc.
    Inventors: Martin M. Bednar, Cordell E. Gross, G. Roger Thomas, Linda J. Gross
  • Anti-CD18 antibodies in stroke
    Patent number: 5914112
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: June 22, 1999
    Assignees: Genentech, Inc., Univ. of VT and State Agricultural College
    Inventors: Martin M. Bednar, Cordell E. Gross, G. Roger Thomas
  • Use of relaxin in the treatment of bradycardia
    Patent number: 5478807
    Abstract: The invention concerns the use of relaxin or another compound capable of specific binding of a relaxin receptor in the heart in the cardiovascular therapy, and specifically in the treatment of acute and chronic heart failure or of a condition characterized by pathologically low heart rate. The invention further concerns the treatment of neurodegenerative diseases using relaxin or other compounds capable of selectively binding a relaxin receptor in the brain.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: December 26, 1995
    Assignee: Genentech, Inc.
    Inventors: Michael Cronin, Phyllis L. Osheroff, G. Roger Thomas, David G. Ward